Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications NK Cells, Other G-Rex®500M-CS

Publication Date: May 13, 2024

G-Rex® bioreactors incubated in Vios™ iDx CR CO2 Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production

Closed-system G-Rex® bioreactors held in Vios iDx CR CO2 incubators showed no bacterial ingress and no viral penetration, supporting contamination-controlled parallel cell therapy manufacturing. In a 14-day full-immersion bacterial challenge, all three test bioreactors showed no growth. All 32 membrane samples passed bacteriophage Phi-X174 penetration testing, with an assay titer below 1 PFU/mL. With ten filled G-Rex® 500M-CS in the chamber, temperature recovered in 5.3 minutes and CO2 in 5.0 minutes after a 60-second door opening. The CultiMaxx shelving kept temperature uniformity within ±0.3 °C, and in-chamber HEPA filtration reached ISO Class 5 in about 5 minutes. Stacked incubators co…

Download Now →

Author: Mary Kay Bates, Dan Fick +4 more

Publications CAR T Cells, NK Cells, T-Cells G-Rex®500M-CS

Publication Date: May 13, 2024

G-Rex® bioreactors incubated in Heracell™ Vios™ CR CO₂ Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production

Closed-system G-Rex® bioreactors held in Vios iDx CR CO2 incubators showed no bacterial ingress and no viral penetration, supporting contamination-controlled parallel cell therapy manufacturing. In a 14-day full-immersion bacterial challenge, all three test bioreactors showed no growth. All 32 membrane samples passed bacteriophage Phi-X174 penetration testing, with an assay titer below 1 PFU/mL. With ten filled G-Rex® 500M-CS in the chamber, temperature recovered in 5.3 minutes and CO2 in 5.0 minutes after a 60-second door opening. The CultiMaxx shelving kept temperature uniformity within ±0.3 °C, and in-chamber HEPA filtration reached ISO Class 5 in about 5 minutes. Stacked incubators co…

Download Now →

Author: Mary Kay Bates, Dan Fick +3 more

Publications NK Cells G-Rex®6 Well Plate

Publication Date: May 10, 2024

Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation

Treating expanded human NK cells with IL-15 and IL-18 for 24 hours before freezing protected them from the cell death that otherwise followed thawing. Healthy-donor NK cells were expanded for 15–20 days in G-Rex® 6-well plates with IL-21-expressing K562 feeder cells and IL-2, then frozen in CryoStor CS5 or CS10. Without pretreatment, about 75% of cells died within 24 hours of thawing by apoptosis driven by granzyme B leaking from cytotoxic granules. Pretreatment with 50 ng/mL IL-15 and 250 ng/mL IL-18 temporarily lowered intracellular granzyme B through degranulation and raised expression of the antiapoptotic gene BCL2L1, giving 100% recovery 24 hours after thaw when frozen in a commercia…

Download Now →

Author: Abdulla Berjis, Deeksha Muthumani +11 more

Publications Other

Publication Date: May 9, 2024

A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report

A 59-year-old woman with diffuse large B-cell lymphoma that progressed after CAR T-cell therapy received autologous cytokine-induced killer (CIK) cells redirected with obinutuzumab and her lymphoma stopped progressing. The cells were produced from 26 mL of peripheral blood using a blinatumomab-based protocol; 25 million mononuclear cells yielded 732 × 10^6 CIK cells after 14 days under Good Manufacturing Practice conditions. She received four infusions at 14-day intervals, escalating from 1 × 10^6 to 3 × 10^6 cells/kg, each preceded by 1,000 mg obinutuzumab. No cytokine release syndrome or neurotoxicity occurred, and the only treatment-emergent adverse effects were persistent neutropenia…

Download Now →

Author: Francesca Elice, Roberta Sommaggio +17 more

Publications CAR T Cells, TCR T Cells G-Rex®10, G-Rex®24 Well Plate

Publication Date: May 7, 2024

NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens

A NOT-gated T cell design (Tmod) made widely expressed antigens usable as cell therapy targets by pairing a CAR activator with an HLA-A*02 inhibitory receptor, restricting killing to tumor cells that have lost HLA-A*02 through loss of heterozygosity. In primary T cells, an EGFR Tmod using a necitumumab scFv and the humanized huPA2.1 blocker killed EGFR+ HLA-A*02- targets while sparing EGFR+ HLA-A*02+ cells, with selectivity windows of 16x to over 65x across four cell lines. Activator EC50s were 2,700 to 5,800 EGFR molecules per cell and blocker IC50s 23,000 to 84,000 HLA-A*02 molecules per cell. Selectivity involved reversible, ligand-dependent removal of the activator from the cell surfa…

Download Now →

Author: Julyun Oh, Charles Kirsh +12 more

Publications NK Cells

Publication Date: May 2, 2024

Optimisation of a primary human CAR-NK cell manufacturing pipeline

Adult peripheral blood NK cells proved a better starting material than cord blood NK cells for manufacturing primary human CAR-NK cells. Cells were expanded on irradiated K562 feeders expressing 41BBL and membrane-bound IL-21 with IL-15, then transduced on day 7 with a baboon envelope-pseudotyped lentivirus carrying an anti-CD19 CAR, averaging 45% transduction at an MOI of 5. Peripheral blood NK cells recovered better from cryopreservation (about 50 to 60% versus about 15%) and expanded on average 10,000- to 100,000-fold over 21 days, while most cord blood NK cells expanded less than 1,000-fold. CAR-NK cells cleared CD19-positive Nalm6 targets within 48 hours with only background IL-6. Th…

Download Now →

Author: Aline Pfefferle, Julian Contet +10 more

Publications CAR T Cells

Publication Date: April 29, 2024

Placental circulating T cells: a novel, allogeneic CAR- T cell platform with preserved T- cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC- derived CAR- T

CD19 CAR-T cells made from placental circulating T cells kept a stem-like, less differentiated profile and controlled lymphoma durably in mice, whereas CAR-T made from healthy adult PBMCs with the same protocol gave only a temporary benefit. Before culture, over 90% of placental T cells were naïve or stem cell memory cells, against about 40% of adult PBMC T cells. After manufacture, placental CAR-T cells had longer telomeres and higher CD27, with lower CD57, LAG3 and TIGIT. Killing of Daudi lymphoma cells was comparable, but IFN-γ release was lower (114.2 vs 261.2 ng/mL). In NSG mice given 3 × 10^6 cells, every placental CAR-T-treated mouse survived and cleared lymphoma over 100 days, whi…

Download Now →

Author: Natalia Ruggeri Barbaro, Theodore Drashansky +6 more

Publications NK Cells G-Rex®100M, G-Rex®24 Well Plate, G-Rex®6M Well Plate

Publication Date: April 22, 2024

PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival

Adding IL-12, IL-15 and IL-18 to PM21-particle stimulation (the CAP method) markedly increased ex vivo expansion of human NK cells from healthy-donor PBMC. Over 14 days, CAP-NK cells expanded a mean 8200-fold versus 1100-fold with PM21-particles alone, and doubled faster on day 9 (18 vs 27 h). In 24-well G-Rex® bioreactors left untouched for 7 days, CAP-NK cells expanded an average 41-fold versus 6-fold for PM21-NK cells, and two donors reached 11,500- and 10,800-fold by day 14 after transfer to larger G-Rex® formats. CAP-NK cells expressed more 4-1BB and CD25, killed SKOV-3 and A549 cancer cells more effectively, had higher basal glycolysis and maximal respiration, survived better withou…

Download Now →

Author: Jeremiah L. Oyer, Tayler J. Croom-Perez +8 more

Publications VST Cells G-Rex®10

Publication Date: April 18, 2024

Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment

In this multicenter phase II trial in pediatric patients with refractory cytomegalovirus, Epstein-Barr virus or adenovirus infection, banked partially HLA-matched third-party virus-specific T cells proved feasible and effective after stem cell transplantation. Suitable products were identified for 75 of 77 queries (97%), and 51 patients received 1–3 infusions at a fixed dose of 2 × 10^7 VSTs/m2. Among 40 evaluable patients treated after transplant, 29 (73%) responded, exceeding the 52% efficacy target; none of four patients treated before transplant responded. Overall survival at one year was 85.3% in responders. Corticosteroids, prior ATG, GVHD history, eculizumab and TA-TMA lowered the…

Download Now →

Author: Michael D. Keller, Patrick J. Hanley +47 more

Publications TIL Cells

Publication Date: April 17, 2024

Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy

Tumor-infiltrating lymphocytes (TILs) were expanded from about one-third of resected head and neck squamous cell carcinoma specimens, and higher stromal TIL percentage was associated with success. Fragments (1–2 mm) of 47 tumor and metastatic lymph node specimens from 33 patients were cultured for 14 days with 1,000 IU/mL IL-2. Seventeen specimens (36.2%) reached the cutoff of 0.8 × 10^5 TILs per fragment; 17 grew insufficiently and 13 (27.6%) were lost to contamination despite gentamicin. Successful cultures averaged 5.5 × 10^5 TILs per fragment and 36.6 × 10^6 total TILs. Among 13 analyzed cultures, CD4+ T cells dominated in 69.2%, and effector memory cells were the main subset in all.…

Download Now →

Author: Sangjoon Choi, Mofazzal Hossain +10 more

Publications CAR T Cells G-Rex®6M Well Plate

Publication Date: April 10, 2024

Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence

Metabolic priming changes how non-viral GD2 TRAC-CAR T cells are manufactured: T cells are activated for three days in low glucose/glutamine TexMACS with IL-7/IL-15, electroporated with a CRISPR-Cas9 RNP plus a Nanoplasmid HDR template, then expanded for seven days in Immunocult XF. At GMP-compatible scale, 20-50 million cells were electroporated on a CTS Xenon system and expanded in G-Rex®6M plates seeded at 10e6 cells per well in 100 mL for six days. Primed products consumed 1.9-fold less glucose and produced 3.4-fold less lactate than controls with comparable day-10 yield, contained 2.3-fold more CD62L/CCR7 double-positive stem cell memory CAR T cells, and reached 28% central memory in…

Download Now →

Author: Dan Cappabianca, Dan Pham +11 more

Publications CAR T Cells, T-Cells G-Rex®24 Well Plate

Publication Date: April 9, 2024

IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity

Confining IL2 signaling to CD8+ T cells gave strong antitumor activity in mice and a favorable nonclinical safety profile. AB248, an attenuated IL2 mutein fused to an anti-CD8β antibody, induced pSTAT5 in human CD8+ T cells with an EC50 of 0.10 nmol/L, over 500-fold more potently than in other cells. A single 1 mg/kg dose of the mouse surrogate CD8-mIL2 produced durable rejection of MC38 tumors in 7 of 10 mice without body weight loss, and outperformed an untargeted not-α IL2 in MC38 and T3 sarcoma models. With anti-PD-1, it achieved complete rejection of anti-PD-1-resistant T3 sarcomas in all treated mice. In cynomolgus monkeys, two weekly doses expanded CD8+ T cells up to 20-fold, with…

Download Now →

Author: Kelly D. Moynihan, Manu P. Kumar +17 more